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Abstract
Background: Ethiopia has the highest proportion of vivax malaria, approximately 40% of all
malaria infections, in contrast to African countries. Chloroquine (CQ) is the drug of choice for the
treatment of Plasmodium vivax infection in the country, although CQ resistant P. vivax (CRPv) has
started to challenge the efficacy of the drug. The present study was conducted to assess the current
status of CRPv at Serbo, Jimma zone, south-west Ethiopia.
Methods: A 28-day in vivo therapeutic efficacy test was conducted from October 2007 to January
2008. Recurrence of parasitaemia and the clinical condition of patients were assessed on each visit
during the follow-up. The levels of haemoglobin (Hb) in the study participants were determined.
The patients' blood drug levels were measured using HPLC. Data was analysed using SPSS for
windows version 10.0. HPLC data was computed using Chem Station for LC 3D systems software.
Results: Of the total 84 patients included in the study, 78 completed their 28-day follow-up, six
of whom being excluded for different reasons. In three children (aged 7, 12 and 13 years),
parasitaemia reappeared within the 28-days follow-up in spite of adequate absorption of the drug
and absence of malaria symptom. In addition, on the day of recurrence of parasitaemia the levels
of chloroquine-desethylchloroquine (CQ-DCQ) were above the minimum effective concentration
(≥100 ηg/ml) in all the three cases, showing that treatment failure could not be attributed to low
level of drug in the patients blood.
Conclusion: Reappearance of the parasite within the 28 days of follow-up is due to parasite
resistance to CQ. The 3.6% (95% CI = -0.038 - 0.0758) prevalence of CRPv malaria in the study
area signals the need for launching monitory activities for CQ resistant P. vivax. Moreover, as
former report from the same country, Debrezeit, also showed the occurrence of CRPv, survey on
CRPv malaria should be made in P. vivax endemic areas in order to estimate the level of burden
across the country.
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Background
In Ethiopia, malaria is seasonal and unstable, causing fre-
quent epidemics [1]. It usually occurs at altitudes < 2,000
meter above sea level. Occasionally, transmission of
malaria occurs in areas previously free of malaria, includ-
ing areas >2,000 meter above sea level, where the micro-
climate and weather conditions are not normally
favourable for malaria. Recent report has indicated that
epidemics have expanded to areas up to 2,400 meter
above sea level [2].
Plasmodium falciparum and P. vivax are the two species
commonly known to cause malaria in Ethiopia account-
ing for 60% and 40% proportion, respectively [3]. Resist-
ance to anti-malarial drug in P. falciparum is well known
since its first report on chloroquine (CQ) in 1998. The
resistance to chloroquine (CQ) necessitated a change to
sulphadoxine-pyrimethamine (SP) as first-line anti-
malarial in Ethiopia. However, recent data has showed
high mean SP treatment failure with 72% rate in some
areas [4]. Consequently, making another change to arte-
mether-lumefantrine (AL) was suggested in 2004. Until
now there has been no report on the parasites resistance
to the last drug [5].
Currently, CQ has been used as first-line drug for treat-
ment of P. vivax infection throughout the country. How-
ever, chloroquine-resistant P. vivax (CRPv) has been
emerging in different parts of the world. The first report of
P. vivax resistant to chloroquine was from Papua New
Guinea in 1989 [6], 30 years after resistance to this drug
was first detected in P. falciparum. In the year that fol-
lowed, isolated incidents of CRPv infections were
reported from Irian Jaya, Indonesia, in 1991 [7], West
Kalimantan, Indonesia, in 1998 [8], India in 2000 [9],
Vietnam in 2000[10], Colombia in 2001 [11], Papua
Indonesia in 2003 [12], Peru in 2003 [13], Brazil in
2007[14], and Dawei, southern Myanmar in 2008[15].
Since P. vivax malaria is rare in most part of the African
continent, reports associated with P. vivax drug resistance,
particularly resistance to CQ is scanty. To the authors'
knowledge, there are only three reports: one from Mada-
gascar [16] and the other two from Ethiopia [17,18]. The
first report on CQ-resistant P. vivax in Ethiopia was from
Debrezeit [17]. According to this report, of 225 patients
who were followed for seven days, 2% failed to respond
to treatment. A very detailed study was also conducted in
the same site after 11 years [18]. In the later study, among
87 subjects involved in the study, parasitaemia re-
appeared in four patients (5%) on day 28 during follow-
up. The level of CQ plus its major metabolite in these sub-
jects were above minimum effective concentration
(MEC), which could confirm presence of drug resistant P.
vivax parasite in the study area [19]. Therefore, the present
study was conducted to assess the current status of CRPv
at Serbo, Jimma zone, southwest Ethiopia. The result of
this study showed that, in three children (aged 7, 12 and
13 years), parasitaemia re-appeared within 28-days fol-
low-up in spite of adequate drug absorption and drug
level above minimum effective concentration.
Methods
Study site
The study was conducted in Serbo Health Center found in
Serbo town, Kersa woreda, Jimma zone, 345 km south-
west of Addis Ababa from October, 2007 to June, 2008
(Figure 1). The study area is located between latitudes
7°35' – 8°00'N, and between longitudes 36°46'-37°14'
E, at altitudes between 1,740 – 2,660 m above sea level
[20]. It has an estimated total population of 329,629 of
which 85% are dependent on agriculture, mainly growing
coffee, chat, maize and fruits [20]. The major health prob-
lem in the woreda is malaria (77%). As the six consecutive
years data (2002–2007) from Serbo Health Center
showed, the number of malaria cases ranged between
3,925 and 22,938, with the peak being during 2004/5.
Plasmodium falciparum (60%) has been more prevalent
than P. vivax (40%), although the overall trend was simi-
lar for the two species. The prevalence seems decreasing
although the number of cases per year is still high. The
period from September to January is considered as the
peak season of malaria transmission in the area. Anopheles
arabiensis is a malaria vector found in Jimma zone [21].
Study participants
Suspected patients seeking medication in Serbo Health
Center were examined for the presence of P. vivax parasite
Map of the study site Figure 1
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monoinfection, on thick and thin film preparations, with
a threshold of 250 parasites/μl or above. Among the
screened patients, those who fulfilled inclusion criteria set
by WHO [22] were recruited for the 28-days in vivo study.
The sample size was calculated based on the expected pro-
portion of P. vivax treatment failures with CQ in the study
population. Assuming a maximum of 5% treatment fail-
ures in a population of infinite size, a precision of +5%,
and a 5% significance level, and expecting loss to follow-
up rate of 15% over a 28-day study, 84 study participants
were included [23].
Treatment and follow-up
In-vivo test
A 28 days in-vivo drug efficacy testing was done according
to the methods recommended by WHO [22]. An in-vivo
test included treatment of symptomatic and parasitaemic
individuals with a known dose of chloroquine, (25 mg
base/kg), administered for three consecutive days (10 mg/
kg on days 0 and 1, and 5 mg/kg on day 2) and the succes-
sive monitoring of the parasitological and/or clinical
response overtime (for 28 days). All drug doses were
administered under supervision of professionals and
physiological complains were recorded at the time of each
visit. Subjects were checked for vomiting for 30 minutes
after ingestion of the drug; those who vomited the first
dose were re-treated with an identical dose provided that
the subject vomited the entire ingested drug. Subjects who
vomited twice were dropped from the study. The study
participants were advised not to take other drugs, except
that patients with axillary temperature ≥ 37.5°C were
treated with paracetamol.
Patients were asked to return for follow-up on days 1, 2,
3, 7, 14, 21, 28, for clinical examination including tem-
perature recording, and on any occasion of malaria like
illness [24]. Thick and thin blood smears were prepared at
the time of all follow-up visits except day1. About 100 μl
of blood sample was collected using EDTA heparinized
capillary tube from lancet pricked finger on filter paper on
days 0, 2 and any day when patients had recurrent parasi-
taemia for measurement of whole blood CQ and DCQ
concentrations.
Patients who did not come for follow-up were traced to
their homes. Those who failed to respond to CQ were re-
treated with quinine sulphate (8 mg base/Kg) plus tetracy-
cline (250 mg), for children older than eight years, and
quinine sulphate plus clindamycine (300 mg) for chil-
dren less than eight years of age three times daily for five
days [13]. All re-treatments were done under supervision.
The patients were followed for five days for any complains
and released after the blood films of the cases were
checked for parasite clearance.
Laboratory procedure
Drug quality analysis
The quality of drug used in the study (chloroquine phos-
phate 250 mg, batch number 1482, Adigrat Pharmaceuti-
cal Factory) was tested for weight variation,
disintegration, dissolution, identification and chloro-
quine hydrochloride injection assay, using the standard
procedures recommended by British pharmacopoeia
[25,26] at the National Laboratory of Drug Administra-
tion and Control Authority of Ethiopia. The batch of drug
used for in vivo efficacy test was confirmed to fulfil all
international specifications set for each mentioned tests.
Parasite identification
Parasites were identified by microscopic observation of
the parasite's morphology using duplicate thick and thin
blood smears taken at enrolment (Day 0). Subsequently,
blood slides were done at subsequent visits (scheduled
and non-scheduled). After fixing the thin film in metha-
nol, both smears were stained with Giemsa (3%, pH 7.2)
for 45 min and the thick films were examined under oil-
immersion for malaria parasites. P. vivax asexual stages
were counted against 200 white blood cells (WBC) or 500
WBC, if the number of asexual parasites was below 10 per
200 WBC, assuming the median total WBC count of
8,000/μl for the study population. Parasite reduction ratio
(PRR) on day of admission and day 2 (after 48 hours),
was evaluated as suggested by White [27] using the for-
mula τ = Po/P2formula (where Po is parasite count on day
0 and P2 parasite count on day 2). Moreover, gametocytes
were counted per 1,000 WBC, based on a mean WBC
count of 8000/μl. Haemoglobin measurement was made
on day 0 and 28 during follow-up and recurrence of para-
sitaemia using Hemocue™ (haemoglobinometer, Angel-
holm, Sweden).
Two experienced laboratory technicians working in Serbo
health center examined each blood smear. All P. vivax-
positive slides on day of admission, 10% of negative slides
picked randomly from slides prepared during follow-up
and all slides on day of recurrence were re-examined by
senior laboratory technician.
Endpoints
Study participants were classified either as 'adequate clin-
ical and parasitological responses', in the absence of para-
site recurrence within 28 days of follow-up, or 'treatment
failure' in case of recurrence of parasitaemia during fol-
low-up (within 28-days). When failures (whatever the
genotype, either same or different) occurred in the pres-Malaria Journal 2009, 8:177 http://www.malariajournal.com/content/8/1/177
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ence of blood chloroquine concentrations (CQ+ DCQ)
above100  ηg/ml, and adequate drug absorption, they
were considered as resistant to CQ.
Chloroquine and desethylchloroquine (DCQ) levels in 
whole blood
Blood drug levels (CQ-DCQ) in patients with recurrent P.
vivax  were measured using HPLC (Agilent 1200 series,
Agilent Technologies, Germany) following the method
described by Bell et al [28] with minor modification
whereby the venous blood was replaced by blood spotted
on filter paper. The LC-system of the HPLC instrument
used was ZORBAX Ecllpse XDB-C18 reversed-phase ana-
lytical column (4.6 × 150 mm ID, 5 μm), with flow rate of
1 ml/min using isocratic mobile phase containing De-ion-
ized water, acetonitrile and triethylamine in percent ratio
of 90%, 10% and 1%, respectively.
Data analysis
Data collected from in vivo therapeutic efficacy test was
double entered and analyzed using SPSS software (version
10.0, Chicago, IL, USA). Kaplan-Meier survival probabil-
ity analysis was used to evaluate treatment out come of
study participants during follow-up period. Accordingly,
data of patients excluded from the study for different rea-
sons, including loss to follow-up, re-infection with P. fal-
ciparum  and vomiting, were included in the analysis
considering them as non-treatment failure cases. Relation-
ship between parasite load and age of study participants
on day of admission was compared using Pearson's corre-
lation. Haemoglobin recovery of patients with adequate
clinical and parasitological responses was compared using
Mann-Whitney U test. Proportion of anaemic cases on day
of admission and 28 were evaluated using Chi-Square test.
In non-normally distributed data (age), median was used
to measure the central tendency. In all analysis, signifi-
cance level was considered at 95% confidence interval. In
addition, HPLC data were computed using Chem Station
for LC 3D systems software.
Ethical clearance
The study protocol was reviewed and approved by the Eth-
ical Review Committee of Addis Ababa University,
Department of Biology. Written informed consent was
obtained from each patients or guardian parent, in cases
when the study subjects were younger than 18 years.
Results
Characteristics of the study population
During the study period, a total of 2,165 patients were
examined for malaria infection and 692 (32%) were pos-
itive for malaria. Of the positive cases, 26.3% (182/692)
were with P. vivax mono-infection; 84 of them who met
all inclusion criteria set by WHO [22] were enrolled in the
study. Median age of the study population was 8 years (9
months to 45 years), and the majority (60.7%, n = 51) of
the cases were males (Table 1). Moreover, large number of
the study population (75%, n = 63) were children <15
years. Of the total 84 cases included in the study, six cases
were excluded during the 28 days follow-up for different
reasons: three of them were re-infected with P. falciparum
on day 14, 21, and 28, respectively were re-treated with
artemether-lumefantrine (AL) or Coartem®; two cases
were loss to follow-up on day 7 and one case re-vomited
his second dose on day 1 (Table 2). Only 78 cases com-
pleted their 28 days follow-up.
Geometric mean parasite count of the study participants
were 2,355.7/μl (95% CI = 408 – 4304). Parasite counts
were the highest (5,243.5 ± 10,831) in children <5 years
as compared to other age groups. Among the study popu-
lation, age and parasite density at day 0 were observed to
have negative correlation (r = -0.276, significant at p =
0.01) (Figure 2).
Treatment response
Since CQ is a fast-acting blood schizonticide drug, para-
site clearance was achieved within 48 to 72 hours in 88%
(n = 74) of study participants. The mean parasite reduc-
tion ratio (PRR) was 227.2/μl after 48 hour (on day 2).
Complete parasite clearance was achieved on day 7 in all
cases. Gametocytes were detected in 12% (n = 10) of the
patients' blood films. In all cases, gametocyte continued
Table 1: Demographic and clinical characteristics of the study 
participants, Serbo town, Jimma zone, Ethiopia
Characteristics At day of admission (Day 0)
Median Age (years) 8 years (9 months – 45 years)
< 5 2 years (9 months – 4 years)
5–14 9 years (5 – 13 years)
15+ 25 years (16 – 45 years)
Sex
M 51 (60.7%)
F 33 (39.3%)
Mean Body Temp. 37.66°C
Febrile (Axillary Temp. ≥ 37°C) 46 (55%)
History of Fever 76 (90.5%)
Haemoglobin level 12.1 (7.5–16.8) ± 1.99 g/dl
Geometric mean parasite 2355.7/μl (95% CI = 408 – 4304)
Geometric mean of gametocyte 102.7/μl (95% CI = 66.3–139)Malaria Journal 2009, 8:177 http://www.malariajournal.com/content/8/1/177
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to appear until day 2 and 3, but cleared on day 7 and did
not re-appear thereafter until the end of the 28 days fol-
low-up period.
Most of the study participants, 55% (n = 46) were febrile,
had axillary temperature ≥ 37.5°C on day of admission,
although the number shown declining to 34.6%, 29.5%,
10.3% on day 1, 2, and 3, respectively. About 8.3% (n =
7) of the total study participants were febrile on the
remaining days (day 7 and 14) of follow-up. About 90.5%
(n = 76) had history of fever for about 48 hours before
admission. Except the 8.9% recorded on day 0 only less
than 3% of the study participant had diarrhoea on day 1
and 2. Similar to the pattern observed for fever, the
number of study participants who had history of vomiting
was the highest on day 0 (37%, n = 31), but the number
decreased down to 21.8% (day 1), 10.3% (day 2), 3.8%
(day 3) and disappeared on day 7 in all cases.
Among patients treated with CQ at therapeutic dose
under supervision, three of them revealed recurrent para-
sitaemia within the 28 days follow-up (on day 14, 25, and
28). In all patients with treatment failure, parasite count
increased from day of admission to day of parasite recur-
rence (Table 3) without complains of malaria symptom
except for the recurrence of parasitaemia. Only one
patient (038) cleared parasites on day 7, while the other
two cleared before 48 hours. In the former case, the para-
site reduction ratio (PRR) after 48 hours was 2.375/μl.
Haemoglobin level determination
The Hb level on day of admission and day 28 were com-
pared using Mann-Whitney U test and the result showed
significant difference (p < 0.01) (Figure 3). Mean propor-
tional recovery of haemoglobin among study participants
with adequate clinical and parasitological responses was
0.11 g/dl. The proportion of anaemic cases on day of
admission was not significantly different (χ2 = 1.69, p =
0.193). However, on day 28, the number of anaemic cases
differed significantly (χ2 = 4.41, p = 0.035). But in the two
patients with treatment failure, there were no difference in
Hb level on day 0 and recurrence. In one of the patients
with treatment failure the level of Hb was improved
despite an increment in level of parasitaemia on day of
recurrence (Table 3).
CQ-DCQ level in patients with treatment failure
Results of the method validation test revealed that the
total percent Coefficient of variation (%CV) of quality
Table 2: Treatment out come of study participants during follow-up period in Serbo town, Jimma zone, southwest Ethiopia
Follow-up days Population at risk Excluded from the study Treatment failure Survival probability 95% confidence interval
Lower limit Upper limit
Day 0 84 0 0 1 0.9455 1
Day 1 84 1 0 1 0.9455 1
Day 2 83 0 0 1 0.9455 1
Day 3 83 0 0 1 0.9455 1
Day 7 83 2 0 1 0.9455 1
Day 14 81 1 1 0.9876 0.9255 0.999
Day 21 79 1 1 0.9751 0.907 0.995
Day 28 77 1 1 0.9625 0.889 0.989
Relationship between age group and parasite count at day of  admission of study participants in Serbo town, Jimma zone,  southwest Ethiopia Figure 2
Relationship between age group and parasite count 
at day of admission of study participants in Serbo 
town, Jimma zone, southwest Ethiopia.
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control samples were < 10% in all runs for each analyte
(CQ and DCQ). Recovery of each analyte was 82.38% and
78.5%, respectively. Calibration curve of excellent linear-
ity was obtained with correlation coefficient 0.995 and
0.998 for CQ and DCQ respectively. The peak area ratio of
analyte (CQ and DCQ) in blood of patients with treat-
ment failure against internal standard (QND) was consid-
ered to quantify the level of drug in their blood. CQ-DCQ
levels in blood of patients with treatment failure showed
that one of the patients was found exposed to CQ before
the start of follow-up as small amount of CQ was detected
in the patient's blood (Table 3). The three of them were
found capable of absorbing the delivered CQ on day 2 as
confirmed by detection of high concentration of CQ,
1030.37 ± 341 (713.4 -1391.2 ηg/ml) in their blood. In
addition, blood of all the patients with treatment failure
was found possessing CQ-DCQ level above the MEC on
day of recurrence of parasitaemia (Table 3).
Discussion
In the study conducted in Serbo Health Centre, three (n =
3) treatment failure was observed. Similar to the reports
from Indonesia and Peru in which treatment failures were
observed in children [8,13,29], the patients with treat-
ment failure were also 7, 12, and 13 years. The increase in
parasite density on day of parasite reappearance com-
pared to enrolment day in cases with treatment failure was
corresponding to the reports of Soto et al., and Baird et al
[11,30] that showed parasitaemia on patients with treat-
ment failure to increase at day of recurrence compared to
that of the day of admission.
According to the protocol of WHO [22] for in vivo anti-
malarial drug efficacy test, resistance is defined as the pres-
entation of signs of severe malaria within the first two
days after monitored treatment, the presence of parasitae-
mia and axillary temperature ≥ 37.5°C between day 3 and
28, presence of parasitaemia on any day between day 7
and 28, irrespective of clinical conditions. In this study all
treatment failures were appeared on day between 7 and 28
and none had complained of malaria symptom. As anae-
mia is a major outcome of malaria illness and treatment
with the appropriate drug will be expected to improve the
patients' haemoglobin (Hb) level with time. However, in
patients with treatment failure lack of Hb recovery on day
of recurrence indirectly proves the presence of undetecta-
ble parasitaemia in their blood after treatment with CQ.
Since drug absorption problem of the patients could be a
cause for the treatment failure, evaluation of the status of
drug absorption of patients with treatment failure had
shown that, the levels of CQ-DCQ was high on day 2 of
CQ treatment. The high levels of drug in blood of the
three patients with treatment failure showed lack of drug
absorption problem. In addition in all cases drug level on
day of recurrence was above MEC. Baird [19], stated that
if the level of drug (CQ-DCQ) at day of recurrence is ≥ 100
ηg/ml, the reappeared parasite should be considered as
resistant to CQ irrespective of its genotype (relapse, recru-
desce or re-infection) and will be classified as chloro-
Table 3: Parasite count, Haemoglobin level and CQ-DCQ level in the blood of Plasmodium vivax malaria patients with treatment failure 
at Serbo, Jimma zone, Ethiopia.
Patient's
Code (day of Recurrence)
Parasite count/μl Haemoglobin level (g/dl) Level of CQ + DCQ (ηg/ml)
Day 0 Day of recurrence Day 0 Day of recurrence Day 0 Day 2 Day of recurrence
038 (28) 480 1920 11.6 11.6 ND 1391.2 145.99
054 (14) 480 960 14.2 14.2 10* 986.5 361.5
057 (25) 680 1040 10.7 12.5 ND 713.4 291.7
Note: ND = not detected; * Only CQ
Haemoglobin recoveries among study participants with ade- quate clinical and parasitological responses in Serbo town,  Jimma zone, southwest Ethiopia Figure 3
Haemoglobin recoveries among study participants 
with adequate clinical and parasitological responses 
in Serbo town, Jimma zone, southwest Ethiopia.
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quine-resistant P. vivax. Therefore, based on the above
criteria, the recurrent parasitaemia observed was due to
resistance, as these parasites are present in the face of CQ
level above the MEC.
In this study the three treatment failures [3.6% (95% CI =
-0.038 - 0.0758)] observed was nearly similar to the study
conducted at Debrezeit, Ethiopia (5%) [18]. However, the
extent of resistance observed in this study was much lower
as compared to the 41% (36/88) case from Iran Jaya,
Indonesia [6], 84% from Papua, Indonesia [12], and 34%
in Myanmar [15] where CRPv is common.
CQ is still drug of choice for treatment of P. vivax malaria
in the study area. However, the emergence of CRPv
malaria in the study area signals the need for regular mon-
itoring activities of CQ resistant P. vivax in malaria
endemic area of the country. The trend observed in Indo-
nesia is good example to estimate the severity of the bur-
den. A decade ago, the level of CRPv in Indonesia was
similar to the current situation of Ethiopia. After 14 years,
however, the level of CRPv increased to about 84% [12] in
some area and enforced looking for other alternative ther-
apy. Therefore, unless proper drug utilization is imple-
mented and CRPv is monitored, the resistant strains could
spread in the community within short period.
Conclusion
This study confirmed the emergence of CRPv strains in
Serbo town, Jimma zone, southwest Ethiopia. Moreover,
as former report from the same country, Debrezeit, also
showed the occurrence of CRPv, country wide survey on
CRPv malaria should be made in P. vivax endemic areas
for current estimate of the level of burden.
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